Eli Lilly and Company has granted a voluntary license to challenger Natco Pharma Limited for baricitinib in India, ending what could have potentially escalated into a high-decibel and divisive tussle over access and availability of the therapy for the treatment of COVID-19.
The US firm on 17 May said that Natco had been issued a royalty-free, non-exclusive voluntary license to further accelerate...







